A phase 2 study of capecitabine and concomitant radiation in women with advanced breast cancer.

ABSTRACT:

Purpose

To examine the response rate of gross chemo-refractory breast cancer treated with concurrent capecitabine (CAP) and radiation therapy in a prospective Phase II study.

Methods and materials

Breast cancer patients with inoperable disease after chemotherapy, residual nodal disease after definitive surgical resection, unresectable chest wall or nodal recurrence after a prior mastectomy, or oligometastatic disease were eligible. Response by RECIST criteria was assessed after 45 Gy. Conversion to operable, locoregional control, and grade ≥3 toxicities were assessed. The first 9 patients received CAP 825 mg/m² twice daily continuously. Because of toxicity, subsequent patients received CAP only on radiation days. Kaplan-Meier analysis was used to estimate overall

SUBMITTER: Woodward WA 

PROVIDER: S-EPMC6072264 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature